Telomerase Activating Compounds for Niche Fertility Applications

Publication ID: 24-11857516_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Telomerase Activating Compounds for Niche Fertility Applications,” Published Technical Disclosure No. 24-11857516_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857516_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,516.

Summary of the Inventive Concept

The present inventive concept discloses specialized telomerase activating compounds and systems for promoting fertility in unique operational environments, such as high-altitude settings, radiation exposure, disaster relief scenarios, and compromised immune systems.

Background and Problem Solved

The original patent disclosed telomerase activating compounds for general fertility applications. However, these compounds may not be effective or suitable for specific, high-stress environments. The present inventive concept addresses this limitation by adapting the compounds and systems for these niche applications, providing a targeted solution for individuals in need.

Detailed Description of the Inventive Concept

The inventive concept comprises telomerase activating compounds and systems tailored for specific, high-stress environments. For instance, Claim 1 discloses a system for promoting fertility in high-altitude environments, comprising a telomerase-activating compound and a delivery mechanism adapted for use at elevated atmospheric pressures. Claim 2 describes a method for enhancing fertility in a subject exposed to radiation, involving the administration of a telomerase-activating compound in conjunction with a radioprotective agent. Similarly, Claims 3-5 detail fertility treatment kits, systems, and methods for disaster relief scenarios, chemotherapy, and compromised immune systems, respectively. These specialized solutions ensure optimal fertility promotion in these unique operational environments.

Novelty and Inventive Step

The present inventive concept introduces novel, non-obvious variations of telomerase activating compounds and systems, specifically designed for niche fertility applications. The inventive step lies in the adaptation of the original compounds and systems to address the unique challenges and requirements of these high-stress environments.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include customized telomerase activating compounds and systems for other specialized environments, such as extreme temperatures, high-stress occupations, or specific genetic conditions. These variations would further expand the scope of the inventive concept, ensuring broad conceptual coverage.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in the fertility and reproductive health industries, particularly in niche markets catering to individuals in high-stress environments. Target industries may include disaster relief organizations, high-altitude research stations, and specialized fertility clinics. The inventive concept's unique value proposition lies in its ability to provide targeted, effective fertility solutions for these underserved markets.

CPC Classifications

SectionClassGroup
A A61 A61K31/09
A A61 A61K31/137
A A61 A61K31/4025
A A61 A61K31/4545
A A61 A61K31/5377
A A61 A61K31/66
A A61 A61P15/08

Field of Art

Reproductive medicine, pharmaceutical compositions, and telomerase activation technologies with a focus on fertility enhancement and cellular interventions

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in molecular biology, pharmacology, or reproductive medicine, possessing expertise in compound design, cellular signaling, and therapeutic interventions for fertility-related applications

Obviousness Rationale

A person having ordinary skill in the art would recognize that the PTD's variations represent predictable extensions of the source patent's core telomerase activation technology by applying known methodological adaptations to specific environmental and physiological contexts. The disclosed variations demonstrate systematic modifications that a skilled practitioner would naturally explore when considering fertility preservation across diverse challenging scenarios. These adaptations represent logical combinations of known techniques with the foundational telomerase activation compounds disclosed in the source patent.

Obvious Combinations & Variations

Source Patent Element
Telomerase activating compounds for fertility promotion
PTD Variation
Specialized delivery mechanisms for high-altitude environments
Obviousness Reasoning
A PHOSITA would recognize that environmental pressure variations require predictable pharmaceutical delivery adjustments, representing a routine engineering design choice with expected outcomes
Source Patent Element
Fertility-associated cell and tissue treatment methods
PTD Variation
Radiation exposure fertility preservation protocols
Obviousness Reasoning
Combining known radioprotective agents with telomerase activating compounds represents a standard protective strategy in cellular intervention technologies
Source Patent Element
Pharmaceutical compositions for fertility enhancement
PTD Variation
Chemotherapy-associated fertility preservation systems
Obviousness Reasoning
Developing protective protocols for compromised physiological states is a predictable extension of existing therapeutic intervention strategies
Source Patent Element
Methods of modulating gonadotropin and steroid hormone expression
PTD Variation
Immunocompromised subject fertility promotion techniques
Obviousness Reasoning
Adapting fertility enhancement protocols to specific immune system conditions represents a logical and foreseeable technological progression
Source Patent Element
Telomerase activation for cellular intervention
PTD Variation
Disaster relief fertility preservation kits
Obviousness Reasoning
Creating portable, adaptable medical intervention systems is a standard approach in emergency and limited-resource medical technologies
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in the present publication would have been obvious to a person having ordinary skill in the art at the time of invention, with a reasonable expectation of success, when considering the teachings of US Patent 11857516 in combination with standard pharmaceutical and medical intervention methodologies. The systematic adaptations represent predictable technological extensions that do not rise to the level of non-obvious innovation.

Original Patent Information

Patent NumberUS 11,857,516
TitleTelomerase activating compounds for use in fertility and related applications
Assignee(s)Neuromagen Pharma, Ltd.